Oppenheimer & Co. Inc. Purchases 1,369 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Oppenheimer & Co. Inc. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 18,143 shares of the biopharmaceutical company's stock after buying an additional 1,369 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in Regeneron Pharmaceuticals were worth $11,507,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $25,000. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $28,000. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares during the last quarter. Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $32,000. Finally, Curat Global LLC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $32,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $511.92 on Tuesday. The stock has a 50-day moving average price of $557.15 and a 200-day moving average price of $638.15. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The firm has a market cap of $55.27 billion, a PE ratio of 13.03, a price-to-earnings-growth ratio of 1.87 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business's quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $9.55 earnings per share. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.69%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. The Goldman Sachs Group decreased their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research note on Monday, June 2nd. Royal Bank Of Canada cut shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective on the stock. in a research note on Friday, May 30th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.